Blood clots form inside the heart when blood pools or moves too slowly through a chamber, when the inner lining of the heart is damaged, or when the blood itself becomes unusually prone to clotting. The most common cause by far is atrial fibrillation, an irregular heart rhythm that lets blood sit and stagnate in the upper chambers. But heart attacks, weakened heart muscle, artificial valves, and inherited clotting disorders can all trigger clot formation as well.
A clot inside the heart is dangerous because it can break loose and travel to the brain (causing a stroke), the lungs, or other organs. Understanding what creates these clots helps explain why certain heart conditions carry such serious risks.
Three Conditions That Set the Stage
Every blood clot, whether it forms in a leg vein or inside the heart, depends on some combination of three factors: blood that isn’t moving well, damage to the surface it flows against, and blood that clots more easily than normal. In the heart, each of these plays out in specific ways.
Slow or stagnant blood is the biggest factor for most cardiac clots. The heart has small pouches called appendages attached to each upper chamber. The left atrial appendage is long with a narrow opening, which naturally predisposes it to sluggish flow. This pouch is the single most common site where clots form inside the heart, even in people with a normal rhythm.
Damage to the heart wall matters too. After a heart attack, the injured muscle tissue triggers an inflammatory response that makes the surface “stickier” to passing blood cells. And certain conditions make the blood itself hypercoagulable, meaning it tips toward clotting even without the other triggers.
Atrial Fibrillation: The Leading Cause
Atrial fibrillation (AFib) is an irregular, often rapid heart rhythm in the upper chambers. Instead of contracting in a coordinated squeeze, the atria quiver chaotically. That quivering means blood doesn’t get pushed out completely with each beat. It pools, especially in the left atrial appendage, and pooled blood clots.
AFib also causes the left atrium to gradually stretch and enlarge over time, which amplifies the stagnation problem. A bigger chamber with weaker contractions means even more blood sitting still. This is why stroke prevention with blood thinners is a central part of AFib management, not just rhythm control.
Doctors estimate each person’s stroke risk from AFib using a scoring system that accounts for age, sex, heart failure, high blood pressure, diabetes, and prior strokes. People who score high on this scale face an annual stroke risk above 2%, which is significant enough that blood thinners clearly outweigh their bleeding risks. For people with lower scores, the benefit is smaller and the decision becomes more nuanced.
Heart Attack Damage
A heart attack kills a section of heart muscle, and that dead tissue can become a breeding ground for clots. The damaged wall stops contracting normally. It may become completely still (akinetic) or even bulge outward with each heartbeat (dyskinetic). Blood swirls against this abnormal surface instead of being pushed forward, and the inflammatory chemicals released by dying tissue further encourage clotting.
Most of these clots form quickly. Roughly 90% of post-heart attack clots develop within two weeks of the event. The larger the area of damage, the higher the risk, because bigger dead zones create more wall motion abnormality and more stagnant flow. In some cases, the damaged wall balloons out permanently into an aneurysm, creating a lasting pocket where blood can pool and clot for months or years after the original heart attack.
Current guidelines from the American Heart Association recommend blood thinners for at least three months when a clot is found after a heart attack, followed by repeat imaging. If the clot has dissolved by that point, stopping the blood thinner is generally reasonable. For clots that form long after the initial heart attack, treatment typically continues for three to six months, with some patients staying on blood thinners indefinitely depending on their individual risk.
Weakened Heart Muscle
Dilated cardiomyopathy is a condition where the left ventricle, the heart’s main pumping chamber, stretches out and weakens. The enlarged chamber can’t push blood out efficiently, so blood lingers inside it. This stagnation follows the same principle as AFib clots, just in a different chamber.
A key number here is the ejection fraction, which measures what percentage of blood the heart pumps out with each beat. A healthy heart ejects about 55% to 70%. When the ejection fraction drops well below that, clot risk rises meaningfully. For patients whose ejection fraction eventually improves above 35% (through medication or other treatment) and whose clot resolves on imaging, doctors may consider stopping blood thinners. For those whose hearts remain weak, longer or even indefinite treatment is often the path forward.
Dilated cardiomyopathy has many causes of its own, including viral infections, long-term heavy alcohol use, certain chemotherapy drugs, and genetic factors. Regardless of the underlying cause, the clot-forming mechanism is the same: a big, weak chamber that can’t clear blood fast enough.
Artificial Heart Valves
Replacement heart valves, particularly mechanical ones made of metal and carbon, create an artificial surface that blood naturally wants to clot against. The body recognizes these materials as foreign, and the flow patterns around a prosthetic valve differ from a natural one, with areas of turbulence and low flow that promote clotting.
Mechanical valves on the left side of the heart develop clots at a rate of 0.5% to 8% even with blood-thinning medication. Valves on the right side carry a much higher risk, around 20%, likely because blood pressure and flow speed are lower on that side. Biological tissue valves (made from pig or cow tissue) carry a substantially lower clot risk than mechanical valves, which is one reason patients and surgeons weigh the tradeoff carefully: mechanical valves last longer but require lifelong blood thinners, while tissue valves may eventually wear out but need less aggressive anticoagulation.
Blood Clotting Disorders
Sometimes the problem isn’t the heart itself but the blood flowing through it. Inherited and acquired clotting disorders shift the balance toward excessive clot formation throughout the body, including inside the heart.
The most commonly encountered genetic mutations are Factor V Leiden and a prothrombin gene variant. Both are relatively frequent in the population but are considered weak risk factors on their own. Rarer inherited conditions, like deficiencies in the natural anticlotting proteins (antithrombin, protein C, or protein S), are less common but carry stronger clotting risks.
Antiphospholipid syndrome is an acquired autoimmune condition that deserves special mention. Patients with heart attacks or strokes who also have elevated antiphospholipid antibodies are significantly more prone to recurrent events. Certain blood cancers, particularly those driven by a mutation called JAK2, also increase the risk of clots in the coronary arteries and elsewhere.
These disorders often come to light when someone has a clot at an unusually young age or in an unusual location, prompting doctors to order specialized blood tests. A clotting disorder doesn’t always act alone. It frequently combines with one of the heart-related causes above, tipping a borderline situation into actual clot formation.
How Heart Clots Are Detected
The standard first test is a transthoracic echocardiogram, the familiar ultrasound where a technician presses a probe against your chest. It’s noninvasive and widely available, but its sensitivity for detecting cardiac clots and other abnormalities is around 65% to 70%. That means it misses roughly one in three cases.
When suspicion is high but the standard echo is inconclusive, doctors turn to a transesophageal echocardiogram, where a small ultrasound probe is passed down the throat to sit right behind the heart. This approach picks up abnormalities about 93% to 95% of the time. It’s particularly superior for visualizing the left atrial appendage (the most common clot location in AFib) and for evaluating artificial valves, where the standard chest ultrasound drops to about 50% sensitivity.
Cardiac MRI is another option that has become increasingly important, especially for detecting clots in the left ventricle after a heart attack. It offers excellent contrast between clot tissue and normal heart muscle, making it a valuable tool when echocardiography results are uncertain.
What Raises Your Overall Risk
Beyond the specific conditions above, several common factors increase the likelihood of clots forming in the heart. High blood pressure damages the inner lining of blood vessels and heart chambers over time, making surfaces more clot-prone. Diabetes promotes inflammation and changes in blood chemistry that favor clotting. Obesity increases circulating levels of clotting factors. Smoking damages blood vessel walls and makes platelets stickier.
Age is a major independent factor. The risk of AFib, heart attacks, cardiomyopathy, and clotting disorders all climb with age, and these risks compound each other. A 75-year-old with AFib and diabetes faces a meaningfully higher clot risk than a 50-year-old with AFib alone, which is exactly why risk scoring tools weigh age so heavily in treatment decisions.